NewLimit is Bringing Longevity Medicines to Human Trials with New Funding Led by Founders Fund

NewLimit, radically extending human healthspan, led by Jacob Kimmel, Brian Armstrong, Blake Byers, and the team, has closed a $435M Series C led by Founders Fund alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others.

The company plans to begin human clinical trials next year following the discovery of a prototype therapy that reversed cellular aging markers in aged human liver cells. The milestone marks a significant step toward translating aging reprogramming research into potential treatments for age-related diseases.

Developing Medicines to Reverse Cellular Aging.

NewLimit is developing therapies designed to restore youthful function in aging cells through epigenetic reprogramming, an emerging field that seeks to reverse age-related cellular changes. The company believes these therapies could eventually help treat age-related diseases and extend healthy lifespan.

After building AI and genomics platforms to discover reprogramming therapies, NewLimit has advanced programs across metabolic, vascular, and immune health, including its first therapy aimed at reversing aging markers in liver cells. The company plans to begin human trials next year, providing an early test of whether cellular age reprogramming can translate into clinical benefits in humans.

Looking ahead, NewLimit intends to expand its pipeline with additional therapies targeting multiple aspects of aging and age-related decline.